Skip to Main Content

Paper Details

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
Acta Neuropathol
1
2023
Author NameAffiliation
Julien Masliah-PlanchonInstitut Curie
Franck BourdeautSIREDO Pediatric Oncology Center, Curie Institute
Christelle Dufour
Olivier AyraultINSERM U1021, Institut Curie, PSL Research University, Universite Paris Sud, Universite Paris-Saclay, CNRS
Torsten PietschUniversity of Bonn Medical Center
Martin SillHopp Children's Cancer Center Heidelberg (KiTZ)
Martin SillGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ)
Stefan M PfisterHeidelberg University Hospital
Stefan M PfisterGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ)
Stefan M PfisterGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Stefan M PfisterHeidelberg University Hospital
Stefan RutkowskiUniversity Medical Center Hamburg-Eppendorf
Stefan RutkowskiUniversity Medical Center Hamburg-Eppendorf
Steven C CliffordWolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University
  • 1 - 16

Datasets

Release 1.2